Durable complete response with a short course of streptozotocin plus doxorubicin combination in malignant metastatic insulinoma

J Cancer Res Ther. 2018 Jul-Sep;14(5):1149-1151. doi: 10.4103/0973-1482.188293.

Abstract

Due to the cytotoxic effects of old chemotherapy regimens used in the islet cell tumors, capecitabine plus temozolomide combination has now become the first choice in the treatment of malignant insulinoma (MIoma). We present this case to emphasize and remind that a durable complete response in advanced stage MIoma may be achieved with a short course of streptozotocin plus doxorubicin combination.

Keywords: Doxorubicin; durable response; insulinoma; pancreatic neuroendocrine tumors; short course; streptozotocin.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenoma, Islet Cell / drug therapy*
  • Adenoma, Islet Cell / pathology
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Dacarbazine / administration & dosage
  • Dacarbazine / analogs & derivatives
  • Doxorubicin / administration & dosage*
  • Humans
  • Insulinoma / drug therapy*
  • Insulinoma / pathology
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Remission Induction
  • Streptozocin / administration & dosage*
  • Temozolomide

Substances

  • Streptozocin
  • Dacarbazine
  • Doxorubicin
  • Temozolomide